Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session - SARS-CoV-2 and cancer

LBA60 - Prospective data of >20,000 hospitalised patients with cancer and COVID-19 derived from the International Severe Acute Respiratory and emerging Infections Consortium WHO Coronavirus Clinical Characterisation Consortium: CCP-CANCER UK


21 Sep 2021


Mini oral session - SARS-CoV-2 and cancer


COVID-19 and Cancer

Tumour Site


Tom Drake


Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741


T. Drake1, C. Palmieri2, L. Turtle3, E. Harrison4, A. Docherty4, B. Greenhalf5, P. Openshaw6, J.K. Baillie7, M.M.G. Semple8

Author affiliations

  • 1 Dept Of Clinical Surgery, University of Edinburgh,, EH8 9YL - Edinburgh/GB
  • 2 Cancer Medicine Department, NHS Liverpool Clinical Laboratories - Royal Liverpool University Hospital NHS Trust, L69 3GA - Liverpool/GB
  • 3 Tropical Infectious Disease Unit, Liverpool University Hospitals NHS Foundation Trust., L7 8XP - Liverpool/GB
  • 4 Usher Institute, University of Edinburgh, EH16 4UX - Edinburgh/GB
  • 5 Department Of Molecular And Clinical Cancer Medicine, University of Liverpool, L69 3GE - Liverpool/GB
  • 6 National Heart And Lung Division,, Imperial College London,, SW3 6LY - London/GB
  • 7 Roslin Institute,, University of Edinburgh, EH25 9RG - Edinburgh/GB
  • 8 Nihr Health Protection Unit In Emerging And Zoonotic Infections And Centre For Excellence In Infectious Disease Research, University of Liverpool, L69 3BX - Liverpool/GB


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract LBA60


The International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) WHO Clinical Characterisation Protocol (CCP) UK has collected complete data from 195,000 COVID-19 patients in the UK as of 12th August 2021. Within this consortium CCP-CANCER-UK has been established to study the effects of COVID-19 in hospitalised patients with cancer.


Patients admitted with proven SARS-CoV-2 infection and registered on CCP-UK from 17th January onwards in 258 healthcare facilities in the UK. Case report forms were used to identify patients with a history of malignant neoplasm or on active treatment for cancer. Analysis is restricted to outcome of patients who were admitted >14 days before data extraction. Patients with a history of cancer and on active treatments were compared to those patients with no history of cancer.


As of 12th August 2021 of the 195,492 participants 15,250 (7.8%) had a history of cancer (Hx Ca) and 5,357 (2.7%) were on active cancer treatment (Act Tx). Patients with cancer were less likely to receive critical care: Hx Ca adjusted odds ratio (aOR) 0.83, 95%CI 0.72 to 0.95, p < 0.001, Act Tx aHR 0.68, 95% CI 0.62 to 0.74, p <0.001. In hospital mortality 23.6% no cancer, 38.9% Hx Ca and 37.6% (aHR Hx Ca: 1.18, 95%CI 1.10 to 1.27, p <0.001, Act Tx: aHR 1.57, 95%CI 1.48 to 1.66, p <0.001). Younger cancer patients, particularly on Act Tx, were more likely to die than similar aged no Ca patients (Act Tx <50 yrs aHR 5.22, 95%CI 4.19 to 6.52, p <0.001). Data will be presented that show over the course of the pandemic, mortality in cancer patients was higher throughout and did not parallel the downward trends seen in patients with no history of cancer.


Europe’s largest prospective hospitalised COVID-19 dataset continues to demonstrate that cancer is independently associated with mortality with younger patients remaining at increased relative risk. Cancer patients face unique risks from the SARS-CoV-2 pandemic. Ongoing vaccination/mitigation studies need to recruit cancer patients to understand the degree of protection afforded in this at risk population.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

University of Oxford.


Has not received any funding.


C. Palmieri: Financial Interests, Personal, Invited Speaker, Advisory boards,conference attendance and research funding: Pfizer, Roche, Eli Lilly , Novartis, Daiichi Sankyo, Seattle Genetics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.